This is a preview of subscription content, log in via an institution to check access.
Notes
funded by Novartis Pharmaceuticals
Reference
Stellato D, et al. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective. PharmacoEconomics : 20 May 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01028-3
Rights and permissions
About this article
Cite this article
Ribociclib + NSAI may be cost effective for advanced breast cancer in Canada. PharmacoEcon Outcomes News 879, 24 (2021). https://doi.org/10.1007/s40274-021-7747-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7747-3